亚洲国产成人久久77-亚洲国产成人久久99精品-亚洲国产成人久久精品hezyo-亚洲国产成人久久精品动漫-人妖hd-人妖ts在线,一本道高清DVD在线视频,2020亚洲永久精品导航,国产久久视频在线视频观看

當前位置: 首頁 JCRQ2 期刊介紹(非官網)
Cardiovascular Drugs And Therapy

Cardiovascular Drugs And TherapySCIE

國際簡稱:CARDIOVASC DRUG THER  參考譯名:心血管藥物和治療

  • 中科院分區

    3區

  • CiteScore分區

    Q1

  • JCR分區

    Q2

基本信息:
ISSN:0920-3206
E-ISSN:1573-7241
是否OA:未開放
是否預警:否
TOP期刊:否
出版信息:
出版地區:UNITED STATES
出版商:Springer US
出版語言:English
出版周期:Bimonthly
出版年份:1987
研究方向:醫學-心血管系統
評價信息:
影響因子:3.1
H-index:63
CiteScore指數:8.3
SJR指數:0.973
SNIP指數:0.814
發文數據:
Gold OA文章占比:26.52%
研究類文章占比:73.27%
年發文量:101
自引率:0
開源占比:0.2471
出版撤稿占比:0
出版國人文章占比:0.14
OA被引用占比:0.3466...
英文簡介 期刊介紹 CiteScore數據 中科院SCI分區 JCR分區 發文數據 常見問題

英文簡介Cardiovascular Drugs And Therapy期刊介紹

Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.

Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.

Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.

期刊簡介Cardiovascular Drugs And Therapy期刊介紹

《Cardiovascular Drugs And Therapy》自1987出版以來,是一本醫學優秀雜志。致力于發表原創科學研究結果,并為醫學各個領域的原創研究提供一個展示平臺,以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述,從廣泛的視角提供當前感興趣的研究主題的新見解,或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單,目前已被權威數據庫SCIE收錄,得到了廣泛的認可。

該期刊投稿重要關注點:

Cite Score數據(2024年最新版)Cardiovascular Drugs And Therapy Cite Score數據

  • CiteScore:8.3
  • SJR:0.973
  • SNIP:0.814
學科類別 分區 排名 百分位
大類:Medicine 小類:Pharmacology (medical) Q1 35 / 272

87%

大類:Medicine 小類:Cardiology and Cardiovascular Medicine Q1 57 / 387

85%

大類:Medicine 小類:Pharmacology Q1 65 / 313

79%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎,針對的是前四年發表的論文的引文。CiteScore的意義在于,它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法,而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Cardiovascular Drugs And Therapy 中科院分區

中科院 2023年12月升級版 綜述期刊:否 Top期刊:否
大類學科 分區 小類學科 分區
醫學 3區 PHARMACOLOGY & PHARMACY 藥學 CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統 3區 4區

中科院分區表 是以客觀數據為基礎,運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據,得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次,類似于“優、良、及格”等。最開始,這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區Cardiovascular Drugs And Therapy JCR分區

2023-2024 年最新版
按JIF指標學科分區 收錄子集 分區 排名 百分位
學科:CARDIAC & CARDIOVASCULAR SYSTEMS SCIE Q2 67 / 220

69.8%

學科:PHARMACOLOGY & PHARMACY SCIE Q2 126 / 354

64.5%

按JCI指標學科分區 收錄子集 分區 排名 百分位
學科:CARDIAC & CARDIOVASCULAR SYSTEMS SCIE Q2 69 / 220

68.86%

學科:PHARMACOLOGY & PHARMACY SCIE Q2 125 / 354

64.83%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異,此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此,JCR將期刊按照學科門類和影響因子分為不同的分區,這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計
  • 國家/地區數量
  • USA106
  • England105
  • CHINA MAINLAND86
  • Italy31
  • GERMANY (FED REP GER)29
  • Netherlands23
  • Japan21
  • Spain20
  • Greece18
  • Canada16

本刊中國學者近年發表論文

  • 1、The Function and Therapeutic Potential of Circular RNA in Cardiovascular Diseases

    Author: Wang, Kai; Gao, Xiang-Qian; Wang, Tao; Zhou, Lu-Yu

    Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 181-198. DOI: 10.1007/s10557-021-07228-5

  • 2、The Function and Regulation of Platelet P2Y12 Receptor

    Author: Li, Xiaohua; Zhang, Guoxing; Cao, Xia

    Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 199-216. DOI: 10.1007/s10557-021-07229-4

  • 3、Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

    Author: Xu, Wenlin; Lv, Meina; Wu, Shuyi; Jiang, Shaojun; Zeng, Zhiwei; Fang, Zongwei; Qian, Jiafen; Chen, Mingrong; Chen, Jiana; Zhang, Jinhua

    Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 2, pp. 363-377. DOI: 10.1007/s10557-021-07232-9

  • 4、Caspofungin Suppresses Brain Cell Necroptosis in Ischemic Stroke Rats via Up-Regulation of Pellino3

    Author: Zhang, Yi-Yue; Tian, Jing; Peng, Zi-Mei; Liu, Bin; Peng, Ya-Wei; Zhang, Xiao-Jie; Hu, Zhong-Yang; Luo, Xiu-Ju; Peng, Jun

    Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 9-23. DOI: 10.1007/s10557-021-07231-w

  • 5、Nicorandil Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats, as Evaluated by 7 T Cardiovascular Magnetic Resonance Imaging

    Author: Wan, Yixuan; He, Bo; Zhu, Dongyong; Wang, Lei; Huang, Ruijue; Wang, Shiyu; Wang, Chunhua; Zhang, Mengdi; Ma, Lu; Gao, Fabao

    Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 39-51. DOI: 10.1007/s10557-021-07252-5

  • 6、Early Guideline-Directed Medical Therapy and in-Hospital Major Bleeding Risk in ST-Elevation Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Findings from the CCC-ACS Project

    Author: Li, Ziping; Yang, Pengfei; Geru, A.; Sun, Haonan; Liu, Hangkuan; Song, Xiwen; Jin, Zhengyang; Li, Linjie; Hao, Yongchen; Li, Yongle; Liu, Jing; Zhao, Dong; Zhou, Xin; Yang, Qing

    Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 117-127. DOI: 10.1007/s10557-021-07201-2

  • 7、Differential Expression of LOXL1-AS1 in Coronary Heart Disease and its Regulatory Mechanism in ox-LDL-Induced Human Coronary Artery Endothelial Cell Pyroptosis

    Author: Song, Bangrong; Dang, Haiming; Dong, Ran

    Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 75-87. DOI: 10.1007/s10557-021-07274-z

  • 8、Protective Roles of Xijiao Dihuang Tang on Coronary Artery Injury in Kawasaki Disease

    Author: Zhang, Jian; Zhuge, Yingzhi; Rong, Xing; Ni, Chao; Niu, Chao; Wen, Zhengwang; Lin, Hongzhou; Chu, Maoping; Jia, Chang

    Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 2, pp. 257-270. DOI: 10.1007/s10557-021-07277-w

投稿常見問題

通訊方式:SPRINGER, VAN GODEWIJCKSTRAAT 30, DORDRECHT, NETHERLANDS, 3311 GZ。